Given the safety confirmation with transient CAR mesothelin expression, a second trial (NCT02159716) was conducted in patients with mesothelioma, ovarian cancer, and pancreatic cancer using a lentiviral transduction vector expressing the same murine-based anti-mesothelin second-generation CAR. This evidence concerns the gene MSLN and mesothelioma.